Journal of Bone Oncology最新文献

{"title":"Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieu","authors":"Rajiv Ranjan Kumar ,&nbsp;Nikita Agarwal ,&nbsp;Akshi Shree ,&nbsp;Jaya Kanta Gorain ,&nbsp;Ekta Rahul ,&nbsp;Shuvadeep Ganguly ,&nbsp;Sameer Bakhshi ,&nbsp;Uttam Sharma","doi":"10.1016/j.jbo.2025.100678","DOIUrl":"10.1016/j.jbo.2025.100678","url":null,"abstract":"<div><div>Ewing sarcoma (EwS) is the second most prevalent pediatric bone malignancy, characterized by its aggressive behavior and unfavorable prognosis. The tumor microenvironment (TME) of EwS is shaped by immunosuppressive components, including myeloid-derived suppressor cells, tumor-associated macrophages, and immune checkpoint molecules such as PD-1/PD-L1 and HLA-G. These elements impair anti-tumor immune responses by modulating the function of tumor-infiltrating immune cells, such as regulatory T cells (Tregs), CD8⁺ T cells, and natural killer cells. Chemokines, including CXCL9 and CXCL12, and cytokines, such as transforming growth factor-beta and interleukin-10, further contribute to immune suppression and promote metastatic dissemination. Recent advances in immunotherapy have highlighted the therapeutic potential of modulating immune cells and signaling pathways to enhance anti-tumor immunity. This review provides a comprehensive analysis of the complex immune landscape within the EwS TME, focusing on the mechanistic roles of key immune components and their potential as therapeutic targets. Understanding these interactions could pave the way for innovative treatment strategies to improve clinical outcomes in patients with EwS.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100678"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone cement implantation syndrome in patients with cemented endoprostheses for metastatic bone disease in the femur","authors":"Thea Hovgaard Ladegaard ,&nbsp;Jakob Stensballe ,&nbsp;Michael Mørk Petersen ,&nbsp;Michala Skovlund Sørensen","doi":"10.1016/j.jbo.2025.100677","DOIUrl":"10.1016/j.jbo.2025.100677","url":null,"abstract":"<div><h3>Background</h3><div>Patients with bone metastases in the femur (BMf) may experience pathological fractures requiring surgery with cemented endoprostheses (EPR). At cementation and prosthesis insertion, patients are at risk of experiencing hypoxia, hypotension, cardiac failure and potentially death, known as bone cement implantation syndrome (BCIS). We aimed to 1) investigate the incidence and grade of BCIS in patients with BMf treated with cemented EPR, and 2) examine if the incidence or extent of BCIS has decreased after a change of a combined anesthesiologic and surgical protocol.</div></div><div><h3>Methods</h3><div>We retrospectively assessed patients with BMf operated with cemented EPR in two periods 2017 – 2018 (early cohort) and 2019 – 2020 (late cohort) and stratified before and after the intervention.</div></div><div><h3>Results</h3><div>Comparing the early and late cohorts, 26/86 (32 %) vs. 30/80 (35 %) experienced BCIS, but mild BCIS (grade 0 + 1) was seen in 79 % vs. 86 %, and severe BCIS (grade 2 + 3) in 21 % vs. 14 %. In the late cohort the per-operative use of vasopressors was higher (86 % vs. 59 %, p &lt; 0.001), we found fewer pulmonary embolisms (PE) (p = 0.024), and a trend toward a reduced length of stay (LOS). 30-day survival was lower for patients with grade 0 + 1 compared to grade 2 + 3 (p = 0.03).</div></div><div><h3>Conclusions</h3><div>BCIS occurs in more than 1/3 of patients operated for BMf with cemented EPR. An increased multidisciplinary focus on BCIS may reduce the complications of BCIS, such as PE and LOS.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100677"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain in patients with multiple inherited osteochondromas: Incidence and potential prognostic factors. A retrospective cohort study","authors":"Morena Tremosini ,&nbsp;Mattia Morri ,&nbsp;Cristiana Forni ,&nbsp;Elena Pedrini ,&nbsp;Marina Mordenti ,&nbsp;Maria Gnoli ,&nbsp;Alessia Di Cecco ,&nbsp;Alice Moroni ,&nbsp;Luca Sangiorgi","doi":"10.1016/j.jbo.2025.100672","DOIUrl":"10.1016/j.jbo.2025.100672","url":null,"abstract":"<div><h3>Purpose</h3><div>the purpose of this study was to describe the baseline characteristics, presenting phenotype and treatment interventions for patients diagnosed with multiple osteochondromas who presented with severe pain symptoms.</div></div><div><h3>Methods</h3><div>a retrospective single-centre cohort study was conducted at a Rare Skeletal Disorders Department. Pain symptomatology was measured at the first visit, pain level was reported, varying from 0, absence of pain to 10, maximum pain. Baseline characteristics, pathology phenotype using IOR classification and treatments performed/ongoing as medical, surgical and conservative therapies were collected.</div></div><div><h3>Results</h3><div>a total of 152 patients were enrolled, with a median pain score of 0 and the 25th and 75th percentiles of 0 and 4, respectively. A percentage of 25.7 % (95 % CI of 19.3–33.3) presented at the first visit with moderate/severe pain. Multiple logistic regression confirmed that age was the only factor to be significantly associated with moderate/severe pain and IOR classification was not able to provide a description of the pathology that was associated with a major pain score.</div></div><div><h3>Conclusion</h3><div>from the early stages of multiple osteochondromas diagnosis<strong>,</strong> pain symptoms must be carefully assessed. An increase in age is associated with a worsening of pain; IOR classification of the multiple osteochondromas phenotype does not currently allow an association between the various classes and pain. A re-evaluation of the classification in this light could be an important new element for clinical practice.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100672"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma","authors":"Guannan Bai ,&nbsp;Shaobo Zhao ,&nbsp;Manli Zhao ,&nbsp;Limiao Chen ,&nbsp;Wenhao Chen","doi":"10.1016/j.jbo.2025.100684","DOIUrl":"10.1016/j.jbo.2025.100684","url":null,"abstract":"<div><div>Osteosarcoma is the most common bone malignancy in children and adolescents. Patients with metastatic and recurrent osteosarcoma have poor prognosis. Regorafenib is a multi-kinase inhibitor recommended as a complement to standard chemotherapy in the treatment of advanced osteosarcoma. The mechanisms associated with regorafenib resistance remains unclear.</div><div>In this study we performed transcriptomics, proteomics and phosphorylated proteomics using regorafenib-treated osteosarcoma cell lines (MG-63, HOS-MNNG for transcriptomics, HOS-MNNG for proteomics and phosphorylated proteomics). After comprehensive multiomics and verification analyses of differentially expressed genes, essential genes for the malignancy of osteosarcoma cells were identified. The effects of essential genes on the proliferation, invasion, and migration of osteosarcoma were determined. The study also evaluated their role in the apoptosis of osteosarcoma cells. The up-regulation of essential genes was determined by immunohistochemistry assays.</div><div>Using comprehensive multiomics and verification analyses we found that the CTDSPL2 gene might play a role in the malignancy and Regorafenib resistance in osteosarcoma. In vitro and clinical specimen assays demonstrated that CTDSPL2 promotes the proliferation, invasion and metastasis of osteosarcoma cells, while inhibiting tumor cell apoptosis.</div><div>In conclusion CTDSPL2 was identified as an essential gene for survival of osteosarcoma cells. Knockdown of CTDSPL2 expression significantly inhibited the proliferation, invasion, and metastasis of osteosarcoma cells, suggesting that it is involved in the formation and development of osteosarcoma tumors. Our data showed that CTDSPL2 is a potential therapeutic target for patients with osteosarcoma.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100684"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting lung cancer bone metastasis using CT and pathological imaging with a Swin Transformer model","authors":"Wanling Li ,&nbsp;Xin Zou ,&nbsp;Jie Zhang ,&nbsp;Minghong Hu ,&nbsp;Guanfeng Chen ,&nbsp;Shanshan Su","doi":"10.1016/j.jbo.2025.100681","DOIUrl":"10.1016/j.jbo.2025.100681","url":null,"abstract":"<div><div>Bone metastasis is a common and serious complication in lung cancer patients, leading to severe pain, pathological fractures, and reduced quality of life. Early prediction of bone metastasis can enable timely interventions and improve patient outcomes. In this study, we developed a multimodal Swin Transformer-based deep learning model for predicting bone metastasis risk in lung cancer patients by integrating CT imaging and pathological data. A total of 215 patients with confirmed lung cancer diagnoses, including those with and without bone metastasis, were included. The model was designed to process high-resolution CT images and digitized histopathological images, with the features extracted independently by two Swin Transformer networks. These features were then fused using decision-level fusion techniques to improve classification accuracy. The Swin-Dual Fusion Model achieved superior performance compared to single-modality models and conventional architectures such as ResNet50, with an AUC of 0.966 on the test data and 0.967 on the training data. This integrated model demonstrated high accuracy, sensitivity, and specificity, making it a promising tool for clinical application in predicting bone metastasis risk. The study emphasizes the potential of transformer-based models to revolutionize bone oncology through advanced multimodal analysis and early prediction of metastasis, ultimately improving patient care and treatment outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100681"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel bone metastasis-related gene signature for predicting prognosis, anti-androgen resistance, and drug choice in prostate cancer","authors":"Yu Luo ,&nbsp;Xiaoqi Deng ,&nbsp;Chengcheng Wei ,&nbsp;Zhangcheng Liu ,&nbsp;Liangdong Song ,&nbsp;Kun Han ,&nbsp;Yunfan Li ,&nbsp;Jindong Zhang ,&nbsp;Shuai Su ,&nbsp;Delin Wang","doi":"10.1016/j.jbo.2025.100673","DOIUrl":"10.1016/j.jbo.2025.100673","url":null,"abstract":"<div><h3>Objective</h3><div>Prostate cancer (PCa) often metastasizes to the bone, posing a significant clinical challenge. This study aims to develop a bone metastasis-related risk model for PCa.</div></div><div><h3>Methods</h3><div>Bone metastasis-related genes (BMRGs) were identified through a combination of differential gene expression analysis and WGCNA using GSE32269 and GSE77930 datasets. Consensus clustering analysis was employed to determine the significance of these genes in molecular subtyping of PCa. LASSO-Cox regression analysis was utilized to construct the bone metastasis-related prognostic gene signature (BMRPS). The predictive performance of BMRPS was assessed using ROC curves, Kaplan-Meier survival curves, and a predictive nomogram. The immune landscape heterogeneity of subgroups was analyzed using CIBERSORT, ESTIMATE, and xCell algorithms. Drug sensitivity and molecular docking analysis were performed to identify drugs associated with BMRPS.</div></div><div><h3>Results</h3><div>Forty-four BMRGs associated with the prognosis of PCa were identified. Consensus clustering revealed the pivotal role of these genes in stratifying PCa into three distinct prognostic clusters. The BMRPS, consisting of 14 BMRGs, demonstrated excellent predictive accuracy for prognosis and served as an independent prognostic factor in PCa. BMRPS effectively predicted the overall survival of bone metastatic PCa and differentiated bone metastasis from other metastatic types. BMRPS showed a close correlation with the immune landscape and immunotherapeutic response biomarkers. Additionally, BMRPS was associated with anti-androgen resistance, and AZD8186 was identified as a potential BMRPS-related drug that holds promise for personalized treatment in PCa.</div></div><div><h3>Conclusion</h3><div>BMRPS facilitates the prediction of prognosis and resistance to anti-androgens in PCa. It also offers insights into the molecular mechanisms of bone metastasis and aids in drug selection for the treatment of PCa.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100673"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of preoperative hematocrit and platelet count with morbidity after pathologic fracture fixation","authors":"Mohyeddine El Sayed ,&nbsp;Ryley Zastrow ,&nbsp;Sassine Youssef ,&nbsp;Adam S. Levin","doi":"10.1016/j.jbo.2025.100679","DOIUrl":"10.1016/j.jbo.2025.100679","url":null,"abstract":"<div><h3>Background</h3><div>Anemia and abnormal platelet count are common among patients with cancer and are associated with complications after orthopaedic procedures. We studied associations between these conditions and morbidity within 30 days after surgery for pathologic femur or humerus fracture.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed data from the National Surgery Quality Improvement Project database for 145,030 adults following surgical fixation of a pathologic femur or humerus fracture from 2010 to 2020. Multivariable logistic regressions compared 30-day complications between patients with mild or severe anemia versus those with normal hematocrit and between patients with thrombocytopenia or thrombocytosis versus those with normal platelet count.</div></div><div><h3>Results</h3><div>Likelihood of extended hospitalization (≥6 days) was higher in patients with mild anemia (odds ratio [OR]: 1.47; 95 % confidence interval [CI]: 1.44, 1.51) and severe anemia (OR: 2.14; 95 % CI: 2.06, 2.23). Likelihood of all-cause morbidity was also higher among those with mild anemia (OR: 1.17; 95 % CI: 1.13, 1.21) and severe anemia (OR: 1.35; 95 % CI: 1.28, 1.42). Similarly, likelihood of extended hospitalization was higher in patients with thrombocytopenia (OR: 1.25; 95 % CI: 1.22, 1.29) and thrombocytosis (OR: 1.24; 95 % CI: 1.13, 1.36). Likelihood of all-cause morbidity was also higher for those with thrombocytopenia (OR: 1.12; 95 % CI: 1.07, 1.16) and thrombocytosis (OR: 1.21; 95 % CI: 1.07, 1.37).</div></div><div><h3>Conclusion</h3><div>Preoperative anemia and platelet abnormalities were potentially modifiable risk factors associated with postoperative complications following surgery for pathologic fracture.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100679"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a nomogram for prognosis of bone metastatic disease in patients with esophageal squamous cell carcinoma: A retrospective study in the SEER database and China cohort","authors":"Bo Huang ,&nbsp;Wei-Dong Wang ,&nbsp;Fang-Cai Wu ,&nbsp;Xiao-Mei Wang ,&nbsp;Bu-Qing Shao ,&nbsp;Ying-Miao Lin ,&nbsp;Guo-Xing Zheng ,&nbsp;Gui-Qiang Li ,&nbsp;Can-Tong Liu ,&nbsp;Yi-Wei Xu ,&nbsp;Xin-Jia Wang","doi":"10.1016/j.jbo.2025.100683","DOIUrl":"10.1016/j.jbo.2025.100683","url":null,"abstract":"<div><h3>Purpose</h3><div>Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor worldwide, and individuals with ESCC and bone metastasis (BM) often face a challenging prognosis. Our objective was to identify the risk and prognostic factors associated with BM in patients with ESCC and develop a nomogram for predicting Cancer-Specific Survival (CSS) which following the occurrence of BM.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of data pertaining to ESCC patients with BM registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015, as well as those treated at a Chinese institution from 2006 to 2020. Significant prognostic factors for CSS were assessed through univariate and multivariate Cox regression analyses. Subsequently, a nomogram was developed utilizing the SEER database and externally validated using real-world evidence from a Chinese cohort.</div></div><div><h3>Results</h3><div>A total of 266 patients from the SEER database and 168 patients from the Chinese cohort were included in the analysis. In the SEER cohort, multivariate analysis indicated that chemotherapy, radiotherapy, liver metastasis, brain metastasis, and sex were independent prognostic factors for ESCC with BM. The prognostic nomogram demonstrated areas under the ROC curve (AUCs) of 0.823, 0.796, and 0.800, respectively, for predicting 3-, 6-, and 12-month CSS. In the Chinese validation cohort, the nomogram exhibited acceptable discrimination (AUCs: 0.822, 0.763, and 0.727) and calibration ability.</div></div><div><h3>Conclusion</h3><div>The study developed a prognostic nomogram to predict CSS in ESCC patients with BM, which can help clinicians assess survival and make individualized treatment decisions.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100683"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of myeloma bone disease: When, how often, and for how long?","authors":"Michael Tveden Gundesen ,&nbsp;Fredrik Schjesvold ,&nbsp;Thomas Lund","doi":"10.1016/j.jbo.2025.100680","DOIUrl":"10.1016/j.jbo.2025.100680","url":null,"abstract":"<div><div>The landscape of MM has changed dramatically in recent years. Several new and more effective treatments have been introduced that not only makes patients live longer but also brings them into a deeper remission. This makes the potential total exposure of bone protective treatment much higher but perhaps also less needed. New and more precise imagining techniques have been introduced making detection of bone disease more sensitive, and the introduction of SLiM-CRAB criteria have changed the parameters used in old clinical trials investigating treatment of MM bone disease. New data have also emerged investigating the effect of the RANKL inhibitor denosumab compared to zoledronic acid (ZOL). Randomized trials have investigated longer treatment durations, which becomes more relevant as patients now live longer.</div><div>In addition in this review, data regarding interval between individual treatment, impact of remission status, new data in relation to rebound after discontinuation and of denosumab, as well as the rational for drug holidays before dental procedures will also be discussed.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100680"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting lung metastasis in high-grade Osteosarcoma: The role of CTA Signs, with a Focus on vascular wrapping and intratumoral vascular network","authors":"Zhendong Luo ,&nbsp;Tao Ai ,&nbsp;Zhiqiang Liu ,&nbsp;Litong He ,&nbsp;Yanzhen Hou ,&nbsp;Yulin Li ,&nbsp;Ziyan Zhou ,&nbsp;Xinping Shen","doi":"10.1016/j.jbo.2025.100687","DOIUrl":"10.1016/j.jbo.2025.100687","url":null,"abstract":"<div><h3>Objective</h3><div>Osteosarcoma is a highly malignant bone tumor with a high incidence of lung metastases (LM), significantly impacting the 5-year survival rate of patients. This study aims to predict lung metastasis in osteosarcoma based on computed tomography angiography (CTA) signs.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted involving 89 consecutive patients with osteosarcoma. Clinical features and CTA signs, including age, gender, laterality, primary site, type of bone destruction, T stage, periosteal reaction, tumor length, bone marrow involved length, vascular wrapping, and intratumoral vascular network, were evaluated. Univariate and multivariate logistic regression analyses were used to identify risk factors for LM, followed by receiver operating characteristic (ROC) curve analysis.</div></div><div><h3>Results</h3><div>The vascular wrapping and intratumoral vascular network signs were more frequently observed in LM in patients with osteosarcoma (<em>P</em> &lt; 0.05). The intratumoral vascular network remained an independent risk factor in multivariable regression analysis. ROC curve analysis demonstrated that the area under the curve (AUC) of the logistic regression model was 0.804, indicating good predictive accuracy.</div></div><div><h3>Conclusion</h3><div>Preliminary findings suggest that CTA signs, particularly vascular wrapping and the intratumoral vascular network, may have potential utility in predicting lung metastasis (LM) in osteosarcoma patients. The intratumoral vascular network, in particular, was identified as an independent risk factor.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100687"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143931395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}